Activation of human pro-urokinase by unrelated proteases secreted by Pseudomonas aeruginosa: LasB and protease IV activate human pro-urokinase by Beaufort, Nathalie et al.
Activation of human pro-urokinase by unrelated
proteases secreted by Pseudomonas aeruginosa
Nathalie Beaufort, Paulina Seweryn, Sophie De Bentzmann, Aihua Tang,
Josef Kellermann, Nicolai Grebenchtchikov, Manfred Schmitt, Christian
Sommerhoff, Dominique Pidard, Viktor Magdolen
To cite this version:
Nathalie Beaufort, Paulina Seweryn, Sophie De Bentzmann, Aihua Tang, Josef Kellermann, et
al.. Activation of human pro-urokinase by unrelated proteases secreted by Pseudomonas aerug-
inosa: LasB and protease IV activate human pro-urokinase. Biochemical Journal, Portland
Press, 2010, 428 (3), pp.473-482. <10.1042/BJ20091806>. <hal-00486859>
HAL Id: hal-00486859
https://hal.archives-ouvertes.fr/hal-00486859
Submitted on 27 May 2010
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

 1  
   
- 
ACTIVATION OF HUMAN PRO-UROKINASE BY UNRELATED PROTEASES 
SECRETED BY PSEUDOMONAS AERUGINOSA 
 
Nathalie Beaufort
*,†,1
, Paulina Seweryn
*
, Sophie de Bentzmann
‡
, Aihua Tang
§
, Josef 
Kellermann
ll
, Nicolai Grebenchtchikov
¶
, Manfred Schmitt
*
, Christian P. Sommerhoff
¥
, 
Dominique Pidard
†
, Viktor Magdolen
*
 
 
*
Department of Obstetrics and Gynecology, Technical University of Munich, Ismaninger Str. 
22, D-81675 Munich, Germany; 
†
INSERM, U698, Univ Paris 7-Denis Diderot, 46 rue H. Huchard, 75015 Paris, France; 
‡
Sensing environment and community lifestyle in Pseudomonas aeruginosa, CNRS LISM 
(UPR9027)-Aix-Marseille Université, 31 Chemin Joseph Aiguier, 13402 Marseille Cedex 20, 
France; 
§
Department of Microbiology, University of Mississippi Medical Center, 2500 North State 
St., Jackson, MS 39216, USA;
 
ll
Max-Planck-Institute of Biochemistry, Am Klopferspitz 18, D-82152 Martinsried, Germany; 
¶
Department of Laboratory Medicine, Radboud University Nijmegen Medical Centre, PO Box 
9101, 6500 HB Nijmegen,The Netherlands; 
¥
Department of Clinical Chemistry and Clinical Biochemistry, Ludwig-Maximilians-
University, Nußbaumstr. 20, D-80336 Munich, Germany 
 
Running Title: LasB and protease IV activate human pro-urokinase  
 
Key words: Pseudomonas aeruginosa, LasB, protease IV, human urokinase, plasminogen 
activation system, bacterial invasion 
 
Footnotes 
1
To whom correspondence should be addressed: Nathalie Beaufort, INSERM U698, Hôpital 
X. Bichat, 46 rue H. Huchard, 75015 Paris, France; Tel: (33)140258600; Fax: (33)140258602; 
E-mail: nbeaufortgbb@yahoo.fr 
 
Abbreviations: uPA, urokinase-type plasminogen activator; uPAR, uPA receptor; Plg, 
plasminogen; Pm, plasmin; PAI-1, plasminogen activator inhibitor type-1; MMP, matrix 
metalloproteinase; PIV, protease IV 
 
Biochemical Journal Immediate Publication. Published on 25 Mar 2010 as manuscript BJ20091806
TH
IS
 IS
 N
O
T 
TH
E 
VE
RS
IO
N 
O
F 
RE
CO
RD
 - 
se
e 
do
i:1
0.
10
42
/B
J2
00
91
80
6
Ac
ce
pte
d M
an
us
cr
pt
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
© 2010 The Authors Journal compilation © 2010 Portland Press Limited
 2  
   
- 
SYNOPSIS 
Pathogenic bacteria, including Pseudomonas aeruginosa, interact with and engage the host 
plasminogen (Plg) activation system, which encompasses the urokinase(uPA)-type Plg 
activator, and is involved in extracellular proteolysis, including matrilysis and fibrinolysis. 
We hypothesized that secreted bacterial proteases might contribute to the activation of this 
major extracellular proteolytic system, thereby participating in bacterial dissemination. 
We report that LasB, a thermolysin-like metalloprotease secreted by P. aeruginosa, converts 
the human uPA zymogen into its active form (kcat = 4.9 s
-1
, Km = 8.9 M). Accordingly, while 
the extracellular secretome from the LasB-expressing, pseudomonal strain PAO1 efficiently 
activates pro-uPA, the secretome from the isogenic LasB-deficient strain PDO240 is 
markedly less potent in pro-uPA activation. Still, both secretomes induce some 
metalloprotease-independent activation of the human zymogen. The latter involves a serine 
protease, which we identified via both recombinant protein expression in E. coli and 
purification from pseudomonal cultures, as protease IV (PIV; kcat = 0.73 s
-1
, Km = 6.2 M). In 
contrast, neither secretomes, nor the pure proteases activate Plg. Along with this, LasB 
converts Plg into mini-Plg and angiostatin, while, as previously reported, it processes the uPA 
receptor, inactivates the plasminogen activator inhibitor 1, and activates pro-matrix 
metalloproteinase 2. PIV does not target these factors at all.  
To conclude, LasB and PIV, although belonging to different protease families and displaying 
quite different substrate specificities, both activate the urokinase-type precursor of the Plg 
activation cascade. Direct pro-uPA activation, as also reported for other bacterial proteases, 
might be a frequent phenomenon that contributes to bacterial virulence. 
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INTRODUCTION 
Proteases are present in all living organisms. In mammals, these enzymes are involved in a 
multitude of (patho)physiological processes, both intracellularly, such as protein quality 
control or apoptotic cell death, and extracellularly, such as complement system activation, 
coagulation and fibrinolysis, inflammation, as well as normal cell migration or malignant 
tumor cell invasion [1]. Microorganisms, including pathogenic bacteria, also produce 
proteases, which primarily provide free amino acids and/or participate to house keeping 
functions [2-4]. Interestingly, some of these proteases also regulate the transition from an 
adhesive to an invasive bacterial phenotype, dampen the host innate and acquired defenses, 
and/or damage host tissues [3-6]. Accordingly, a number of microbial proteases have been 
reported, and in some cases demonstrated, as significant virulence factors [2-4, 6].  
One of the host multicomponent systems that is affected by bacterial proteases is the 
plasminogen activation system [7-9]. This major fibrinolytic/matrilytic and inflammatory 
system is composed of the serine (Ser-) protease plasmin (Pm), its precursor plasminogen 
(Plg), the urokinase-type (uPA) and tissue-type (tPA) proteolytic activators of Plg, as well as 
the serpin-type protease inhibitors α2-antiplasmin and plasminogen activator inhibitor type-1 
(PAI-1) [10-12]. Numerous pathogenic bacteria actually interact with this host system through 
either or both (i) binding of Plg via surface-exposed, lysine-rich residues, (ii) production of 
Plg-activating factors, either displaying proteolytic activity (e.g., the outer membrane aspartic 
protease Pla from Yersinia pestis), or functioning as nonproteolytic activators (e.g., the well-
characterized staphylo- or strepto-kinase) and furthermore, (iii) expression of proteases which 
degrade host serpins [2, 7-9]. Altogether, these host/pathogen interactions induce dysregulated 
engagement of the Plg activation system and are thus thought to promote host tissue 
destruction and bacterial dissemination and invasion, which led to the concept of “bacterial 
metastasis”, by analogy to the uPA/Pm-driven progression of invasive cancer cells [2, 7-9]. In 
line with this, we recently demonstrated that aureolysin, a thermolysin-like metalloprotease 
secreted by the Gram-positive bacterium Staphylococcus aureus, does not only disrupt the 
host protease inhibitor network by degrading α2-antiplasmin and PAI-1, but also activates the 
host protease zymogen pro-uPA [13].  
Considering that other pathogenic prokaryotes might hijack this major mammalian proteolytic 
system via direct pro-uPA activation as well, we investigated the capacity of proteases 
secreted by Pseudomonas aeruginosa to do so. P. aeruginosa is a wide-spread opportunistic 
human pathogen, which can provoke local (e.g., from the skin, wounds, as well as respiratory 
and urinary tracts) to systemic, benign to life-threatening infections [14]. Along with this, this 
Gram-negative bacterium, which produces biofilms and displays a high capacity to develop 
resistance to antibiotics, is a frequent cause for nosocomial infections [14]. Among the 
secreted pseudomonal factors, there is an array of proteases, including the metalloproteases 
LasA, LasB (pseudolysin) and alkaline protease (AprA), as well as the Ser-protease protease 
IV (PIV/PrpL) [4, 15, 16]. In addition with these proteases, a high and a low molecular mass, 
Ser-proteases (LepA, ≈ 100 kDa, and PASP, ≈ 18.5 kDa, respectively) have recently been 
identified in the pseudomonal secretome [17-19]. LasB, which is also one of the major 
secreted pseudomonal proteins, is expressed to high levels both in vitro and in vivo, and is an 
acknowledged virulence factor in lung and skin infection models [16]. This 33 kDa protein 
belongs to the thermolysin/M4 family of metalloproteases and accordingly, it shares sequence 
and structure homologies with staphylococcal aureolysin [20, 21]. LasB, thus, appeared as a 
good candidate to display a direct pro-uPA activating capacity. 
Using purified or recombinant bacterial proteases, as well as pseudomonal extracellular 
secretomes, we demonstrate that LasB and PIV, although being unrelated proteases, both 
target and activate human pro-uPA, while leaving Plg proteolytically inactive. This pathway 
is likely to contribute to bacterial invasion [22]. Moreover, whereas LasB processes a number 
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of components of the Plg system including Plg itself, the uPA receptor, its inhibitor PAI-1, as 
well as one major Pm target, the pro-matrix metalloproteinase-2 (pro-MMP-2), PIV does not 
target any of these proteins.  
Biochemical Journal Immediate Publication. Published on 25 Mar 2010 as manuscript BJ20091806
TH
IS
 IS
 N
O
T 
TH
E 
VE
RS
IO
N 
O
F 
RE
CO
RD
 - 
se
e 
do
i:1
0.
10
42
/B
J2
00
91
80
6
Ac
ce
pte
d M
an
us
cri
pt
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
© 2010 The Authors Journal compilation © 2010 Portland Press Limited
 5  
   
- 
EXPERIMENTAL  
Material 
Purified and recombinant proteins. Purified LasB (0.5 mg/ml, ≈ 15 M) isolated from a 
pathogenic strain of P. aeruginosa was from Elastin Products Company (Owensville, MO, 
USA) and had a specific activity of 260 U/mg protein. Native PIV (0.085 mg/ml, ≈ 3.2 M) 
was purified from the extracellular medium of pseudomonal cultures, as reported by Engel 
and co-workers [23]. Recombinant human pro-uPA (1 mg/ml, ≈ 20 M) expressed in 
Escherichia coli, was a kind gift from A.G. Saunders (Grünenthal, Aachen, Germany). 
Human Glu-Plg (2 mg/ml, ≈ 20 M) and Pm (1 mg/ml, ≈ 10 M, 4.6 U/mg), purified from 
plasma, were from Sigma-Aldrich (Saint-Louis, MO, USA). Human active uPA (1 mg/ml, ≈ 
20 M, 100,000 IU/mg), purified from urine, was from ProSpec-Tany TechnoGene (Rehovot, 
Israel). Human recombinant uPA receptor (uPAR, 0.5 mg/ml, ≈ 10 M), encompassing the 
residues 1-281 fused to a carboxyterminal His-tag, was from R&D Systems (Minneapolis, MI, 
USA). Recombinant human PAI-1 (10 μg/ml, ≈ 0.2 M) was from Hyphen Biomed 
(Neuville-sur-Oise, France). 
Antibodies. A chicken polyclonal antibody (Ab) directed to human uPA and strongly reacting 
with the A-chain of the protease has been produced in-house [24], a mouse monoclonal Ab 
directed to uPAR domain 2 (#3932, reacting with amino acids 125-132 [25]) was from 
American Diagnostica (Greenwich, CT, USA), a mouse monoclonal Ab directed to PAI-1 (C-
9, reacting with amino acids 24-158) was from Santa Cruz Biotechnologies (Santa Cruz, CA, 
USA), and a mouse monoclonal Ab directed to poly-histidine was from Qiagen (Penta-His, 
Hilden, Germany). Horseradish peroxidase (HRP-) conjugated Abs against chicken or mouse 
Ig were from Sigma-Aldrich and from Jackson ImmunoResearch (West Grove, PA, USA), 
respectively.  
 
Bacterial strains and preparation of bacterial extracellular secretomes 
The P. aeruginosa, LasB-producing strain PAO1 [26] and the strain PAO1lasB9 (referred to 
as PDO240), in which the lasB gene sequence has been deleted and replaced with a 
spectinomycin resistance cassette [27], were used in this study. Bacteria were grown 
overnight at 37°C with shaking in Luria broth liquid medium, until cells had reached the 
stationary growth phase. Bacterium-free culture supernatants were then obtained by a first 
centrifugation at 6,000 g, followed by a second one at 12,000 g, both for 10 min. Supernatants 
were further filtered through 0.22 μm membranes to provide the conditioned growth media, 
which contain the array of bacterial factors secreted under these experimental conditions, 
including proteases, and are thereafter referred to as the bacterial secretomes, PAO1-Sec and 
PDO240-Sec, respectively. These milieus were immediately frozen in aliquots and stored at -
80°C. 
 
Cloning, expression and purification of recombinant PIV  
The coding sequence of mature PIV (amino acids 212-462; Swiss-Prot Accession Number 
Q9HWK6) was amplified by nested PCR, and 5' and 3' extensions harboring appropriate 
restriction sites (BamHI, HindIII) for cloning were added by additional PCRs. The PCR 
fragment was then inserted into the bacterial expression vector pQE-30 (Qiagen). The 
resulting fusion gene encodes mature PIV preceded by an N-terminal extension of 17 amino 
acids including the (His)6-tag.  
Overnight cultures of transformed XL1 Blue cells (Stratagene, La Jolla, CA, USA) were 
diluted and grown at 37˚C with vigorous shaking in 2xTY medium to an optical density of 
0.7, then induced with 1.5 mM isopropyl β-D-1-thiogalactopyranoside and cultured for 3 
additional hours. After centrifugation, the bacterial pellet was frozen at -20˚C. Cells were 
lyzed in 6 M guanidine hydrochloride, 10 mM Tris-Cl, 100 mM NaH2PO4, 8 mM 2-
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mercaptoethanol, pH 8.0 on a rotating wheel for 2 h at 4˚C. The lysate was then centrifuged at 
10,000 g for 10 min, the supernatant collected and the pH adjusted to 8.0. 
Thereafter, (His)6-tagged PIV was purified via affinity chromatography using a Ni-NTA 
Superflow resin (Qiagen) under denaturing conditions in two subsequent steps. First, proteins 
were washed and eluted by a pH gradient: starting off with 6 M guanidine hydrochloride, 10 
mM Tris, 100 mM NaH2PO4, 8 mM 2-mercaptoethanol, pH 8.0, the column was further 
washed with 8 M urea, 10 mM Tris, 100 mM NaH2PO4, 8 mM 2-mercaptoethanol, pH 8.0, 
7.0, 6.0, and 5.3, respectively. Most of the bound recombinant PIV was finally eluted with the 
same buffer at pH 4.0. In the second purification step, an imidazol concentration gradient was 
used. For binding of PIV, the pH of the eluate of the first column was adjusted to 8.0 and the 
column loaded in the presence of 5 mM imidazol. Subsequently, the column was washed with 
8 M urea, 10 mM Tris, 100 mM NaH2PO4, 8 mM 2-mercaptoethanol, pH 8.0 containing 
increasing concentrations of imidazol: 5, 10, 20, 30 and 40 mM. Finally, PIV was eluted with 
the same buffer containing 200 mM imidazol.  
Prior to refolding, purified PIV was incubated overnight at 20°C in the elution buffer 
containing 10 mM DTT and then dialyzed overnight in a Spectra/Por membrane (cut-off: 10 
kDa) against an 100-fold volume of 4 M urea, 50 mM Tris-HCl, 100 mM NaCl, 0.005% 
Tween-20, pH 8.0. Refolding of PIV was performed in 2 M urea, 50 mM Tris-HCl, 100 mM 
NaCl, 2.2 mM MgCl2, 50 mM glycine, 5 mM reduced glutathione, 0.5 mM oxidized 
glutathione (GSH:GSSG ratio 10:1), 0.005% Tween-20, pH 8.0, in an 100-fold volume of the 
sample at 4 °C for 10 h and subsequently in an 100-fold sample volume of the same buffer 
containing 1 M urea at 4 °C for 72 h. The refolding buffer was then exchanged with 100 mM 
NaCl, 50 mM Tris-HCl, 0.005% Tween-20, pH 8.0, incubated for 12 h, and changed twice. 
Finally, the protein solution was cleared by centrifugation at 12,000 g and the purified protein 
stored in this buffer at -20
o
C. The protein concentration of recombinant PIV was estimated to 
10 g/ml (≈ 0.4 M), as determined on Coomassie-stained gels calibrated with the Page-Ruler 
unstained Protein Ladder from Fermentas Life Sciences (0.2 mg/ml of each protein, 
Helsingbord, Sweden). 
As a control, an irrelevant (His)6-tagged protein (the uPA receptor domain 1, uPAR1-94, 
thereafter referred to as uPAR-D1; [25]) was expressed, purified and refolded using a similar 
procedure as for recombinant PIV.  
 
Exposure of purified pro-uPA, Plg, uPAR and PAI-1 to pseudomonal proteases  
Pro-uPA (200 ng for immunoblot analysis and activity measurement, 5 μg for aminoterminal 
microsequencing), Plg (200 ng for activity measurement, 1 μg for Coomassie blue staining 
and 5 μg for aminoterminal microsequencing), uPAR (20 ng) or PAI-1 (200 ng) were adjusted 
to a 20 μl final volume in 100 mM Tris, 100 mM NaCl, pH 7.5 (Tris/NaCl). Proteins were 
either left untreated for 1 h at 37°C, or exposed (i) to the respective activators of pro-uPA and 
Plg, Pm (45 nM) and uPA (90 nM), (ii) to purified LasB in the range 1-100 nM, (iii) to 
recombinant PIV in the range 7.5-200 nM, or to 200 nM recombinant uPAR-D1, as negative 
control, (iv) to 100 nM native PIV, or (v) to PAO1-Sec or PDO240-Sec diluted in the range 
0.04 to 1 % (v/v) in Tris/NaCl. Some assays were performed in the presence of various 
combinations of the following selective protease inhibitors (Sigma-Aldrich), at the indicated 
finale concentration: 1,10-phenanthroline (OPA), 10 mM; benzamidine, 5 mM; trans-
epoxysuccinyl-L-leucylamido-(4-guanidino)butane (E-64), 10 μM; pepstatin A, 5 μM. After 
incubation, samples were cooled on ice, and frozen before further analysis (see below).  
 
Exposure of fibroblast-derived human pro-MMP-2 to pseudomonal proteases  
Human myofibroblasts were isolated from surgically resected stenotic calcified cardiac valves 
as previously reported [28]. Cell cultures were routinely grown using the Smooth Muscle Cell 
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Growth Medium 2 containing the following growth additives, all from Promocell Bioscience 
(Heidelberg, Germany): fetal calf serum (FCS), 5 % (v/v); basic fibroblast growth factor, 2 
ng/ml; epithelial growth factor, 0.5 ng/ml; insulin, 5 g/ml. For experimental purposes, cells 
between passages 1 and 5 were detached with trypsin, then seeded in 6-well plates (Tissue 
Culture Products, Trasadingen, Switzerland) and cultured up to high density in the same 
medium. Then, they were washed with phosphate-buffered saline solution (PBS), and further 
maintained in culture for 24 h in 1 ml of FCS-free medium. Cell culture medium, which 
contains the array of secreted fibroblast factors, including proteases, was then collected and 
centrifuged at 300 g for 10 min, then at 18,000 g for 30 min, in order to eliminate detached 
cells and debris. In such medium, pro-MMP-2 has been reported to be the major secreted 
gelatinolytic enzyme [28]. For zymography assay 20 l of cell culture medium were left 
untreated as control, or incubated with purified or recombinant pseudomonal proteases, or 
with bacterial secretomes, exactly as described above. For proteolytic activity measurement, 
100 l of cell culture medium were left untreated as control, or exposed to 2 nM LasB or to 
10 nM native PIV, overnight at 37°C. After incubation, samples were cooled on ice, and 
frozen before further analysis (see below).  
 
Immunoblot analysis 
Proteins were denatured in the presence of 2 % (w/v) sodium dodecyl sulfate (SDS) and 5 % 
(v/v) 2-mercaptoethanol for 5 min at 95°C, followed by electrophoresis on 10 or 14% 
polyacrylamide gels (SDS-PAGE) in a Mini-PROTEAN 3 apparatus (Bio-Rad, Hercules, CA, 
USA). For apparent molecular mass (Mr) determination, the Page-Ruler Plus prestained 
Protein Ladder was used as a standard (Mr range, 10,000-250,000, Fermentas Life Sciences). 
Separated proteins were then transferred onto polyvinylidene fluoride membranes (PVDF, 
Pall, Dreieich, Germany) in a semi-dry transfer device (Biometra, Göttingen, Germany). 
Membranes were incubated for 60 min in PBS, pH 7.4, containing 0.1% (w/v) Tween-20 
(PBS-T) and 5 % (w/v) dried skimmed milk, and then
 
overnight at 4°C with the primary Ab 
diluted in the same medium. After washings in PBS-T, membranes were incubated for 60 min 
with the HRP-coupled
 
secondary Ab (dilution 1/10,000), then washed. Peroxidase activity 
was finally developed using
 
the ECL or ECL+ reagent kits (Amersham Biosciences, Little 
Chalfont,
 
U.K) and the corresponding luminescence was revealed by exposure
 
of membranes 
to X-ray sensitive blue films (CEA, Newcastle upon Tyne, England). Films were scanned 
with a GS-800 Calibrated Densitometer (Bio-Rad) and pictures were prepared with the 
PDQuest 7.1.1 software (Bio-Rad). 
 
Aminoterminal microsequencing 
After electrophoresis under reducing conditions, proteins were transferred onto PVDF 
membranes, exactly as described above. Protein bands, visualized by Coomassie blue staining 
(0.1 % w/v), were then excised and subjected to automated Edman degradation in a pulse 
liquid phase sequencer (Procise 492, Applied Biosystems, Foster City, CA). 
 
Gelatin zymography 
For gelatinolytic activity assays, proteins (200 ng of recombinant PIV or uPAR-D1, or 20 μl 
of protease-exposed fibroblast culture medium) were added with 2% (w/v) SDS and separated 
by SDS-PAGE in 10% polyacrylamide gels, added with 0.2 % (w/v) gelatin (Gibco-
Invitrogen, San Diego, CA, USA). Gels were then washed twice for 30 min in a 2.5 % (v/v) 
Triton X-100 solution, developed overnight at 37°C in 0.2 M Tris, 5 mM CaCl2, pH 7.8, and 
finally stained with Coomassie blue (0.1 % w/v). Gels were scanned as described above. 
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Proteolytic activity measurement towards synthetic substrates 
For uPA and Pm activity measurement, samples were placed in a 96-well plate and adjusted 
to a 160 μl final volume in 50 mM Tris, 150 mM NaCl, pH 8.0, in the presence of 0.13 mM 
benzoyl-β-Ala-Gly-Arg-paranitroanilide (-pNA) (Pefachrome uPA, Loxo GmbH, 
Dossenheim, Germany) or in 100 mM Tris, 0.05 % (v/v) Tween-20, 0.01 % (w/v) BSA, pH 
7.5, in the presence of 0.19 mM D-Val-Leu-Lys-pNA (DVLK-902, Molecular Innovations, 
Southfield, MI, USA), respectively. The release of pNA at 37°C was then monitored at 405 
nm in a spectrophotometer (SLT-Labinstruments, Grödig, Austria) over a 30 min time period. 
The initial rate of substrate hydrolysis derived from the data was then expressed as Δ OD, in 
mU/min. 
For PIV activity measurement, 250 to 500 ng of the recombinant PIV, or 500 ng of control 
recombinant uPAR-D1, were placed in a 96-well plate and completed to a 250 μl final volume 
in 50 mM Tris, 100 mM NaCl, 0.005 % (v/v) Tween-20, pH 8, in the presence of 0.3 mM of 
Tosyl-glycyl-prolyl-lysine-4-nitranilideacetate (Roche, Mannheim, Germany), before 
substrate hydrolysis was recorded as described above. 
For MMP-2 activity measurement, samples were placed in a 96-well plate and adjusted to a 
200 μl final volume in 50 mM Tris, 50 mM NaCl, 5 mM CaCl2, pH 7.5, in the presence of 10 
M (7-methoxy-coumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-[2,4-dinitrophenyl]-L-2,3-
diaminopropionyl)-Ala-Arg (M-1895, Bachem, Bubendorf, Switzerland). Substrate hydrolysis 
was then recorded in a spectrofluorimeter (SpectraMax Gemini EM, Molecular Devices, 
Sunnyvale, CA, USA) over a 30 min time period, with excitation and emission wavelengths 
of 355 and 460 nm, respectively.  
 
Determination of the kinetic parameters of pro-uPA activation 
LasB (0.01 nM), native PIV (0.1 nM) or Pm (0.01 nM, standardized by active-site titration 
using 4-methylumbelliferyl p-guanidinobenzoate [29]), were incubated with varying 
concentrations of pro-uPA (0 - 10 µM) in 50 mM HEPES, 150 mM NaCl, 0.01% azide, 
0.01% Triton X-100, pH 7.4. Zymogen activation was followed by recording the release of 7-
amino-4-methylcoumarin (AMC) generated by cleavage of the reporter substrate Boc-Leu-
Gly-Arg-7-amino-4-methylcoumarin (20 µM) by activated uPA. In each experiment, the 
specific activity of uPA towards the reporter substrate was determined using active-site-
titrated uPA (0 – 10 nM) under the same conditions. Substrate cleavage by pro-uPA, LasB, 
PIV or Pm was negligible. Data were recorded every 30 sec for 30 min using a HTS 7000 Bio 
Assay Reader (PerkinElmer, Rodgau-Jügesheim, Germany), with excitation and emission 
wavelength of 360 and 465 nm, respectively.  
The time-dependent increase of AMC was fitted to a modification of an integrated rate 
equation describing a coupled zymogen activation and reporter reaction initially used to 
analyze the activation of plasminogen [30, 31] : AMC(t) = 0.5 · ars · Vz · (t - t0)
2
 + AMC0, 
where AMC(t) and AMC0 are the concentrations of AMC measured at time t and baseline, 
respectively, t0 the delay between the start of the reaction and the first measurement, Vz the 
velocity of zymogen activation, and ars the specific activity of uPA towards the reporter 
substrate. The zymogen activation velocities Vz at different pro-uPA concentrations 
calculated from at least 3 different experiments were subsequently fitted to the Michaelis-
Menten equation to obtain the kinetic parameters Km, kcat and kcat/Km. Both curve fitting steps 
were performed with proFit (Quantum Soft, Uetikon am See, Switzerland) using a Levenberg-
Marquardt algorithm. 
 
Data presentation 
Results are expressed as mean plus standard error of the mean (+SEM) for the indicated
 
number of experiments performed independently. 
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RESULTS  
Activation of human pro-uPA by purified LasB 
To investigate the capacity of pseudomonal LasB to activate pro-uPA, recombinant human 
pro-uPA (200 ng) was first exposed to increasing concentrations (i.e., 1 to 100 nM) of the 
purified bacterial protease for 60 min at 37°C. It is of note that such LasB concentrations are 
comparable to those produced by bacteria in vitro (i.e., up to 500 nM [32]) and actually 
detected in vivo, such as in the airways of patients with cystic fibrosis (i.e., up to 300 nM 
[33]). Immunoblot analysis performed under reducing conditions revealed that LasB 
progressively converts single-chain pro-uPA (Mr  47,000) into two molecular species with 
Mr  29,000 and  17,000 (Fig. 1A). These molecular masses are similar to those of the B- 
and A-chains of uPA, i.e., the catalytic and binding domains of the protease, respectively, as 
they are generated via exposure of pro-uPA to its canonical activator Pm (Fig. 1A). 
Accordingly, aminoterminal microsequencing indicated that these LasB-generated species 
possess aminoterminal sequences Ile-Ile-Gly-Gly and Ser-Asn-Glu-Leu, respectively, 
corresponding to amino acids 159-163 and 1-4 of human pro-uPA. Both fragments are thus 
generated upon hydrolysis of the Lys
158
-Ile
159
 peptide bond within pro-uPA (Table 1), i.e., the 
activation cleavage site. Proteolytic activity measurement using a selective uPA chromogenic 
substrate confirmed that pro-uPA can be readily activated by LasB, with a bacterial protease 
concentration as low as 1 nM and an enzyme/substrate molar ratio of 1/450 (Fig. 1B). On one 
hand, after exposure of pro-uPA (200 ng) to LasB in the range 10-100 nM, the activity of 
LasB-generated uPA reaches up to 75 % of the activity displayed by 200 ng of purified 
human active uPA, used as a positive control (Fig. 1B). On the other hand, LasB-driven pro-
uPA activation is actually comparable to the activation of pro-uPA resulting from exposure to 
Pm in an enzyme/substrate molar ratio of 1/10 (Fig. 1B). It is of note that for a high LasB 
concentration (i.e., 100 nM, Fig. 1A), the A-chain is further converted into a Mr  13,000 
molecular species, bearing a Phe-Ser-Asn-Ile aminoterminus and thus resulting from the 
hydrolysis of the Tyr
24
-Phe
25
 peptide bond within the growth factor domain that makes part of 
the uPA A-chain (Table 1). In contrast, the B-chain remains remarkably stable. 
Complementary experiments showed an efficient, time-dependent activation of pro-uPA by 
LasB, detectable as soon as 15 min following exposure to 10 nM LasB, while a further 
processing of the A-chain is again observed for the longest incubation time (i.e., 5 h; data not 
illustrated). Finally, to characterize the efficiency of pro-uPA activation by LasB, we 
determined the kinetic parameters of the reaction, and found kcat, Km and kcat/Km values of 4.9 
± 0.34 s
-1
, 8.9 ± 1.1 M and 0.55 ± 0.08 M-1 s-1, respectively, to be compared to values 
obtained with active site-titrated Pm, with kcat 4.2 ± 0.13 s
-1
, Km 3.2 ± 0.24 M and kcat/Km 1.3 
± 0.11 M-1 s-1. 
 
Activation of human pro-uPA by bacterial secretomes 
We next explored whether the secretome from a pseudomonal LasB-expressing strain (i.e., 
PAO1), could trigger activation of pro-uPA. Within such a secretome, LasB is both the major 
secreted bacterial protein and one major protease, reaching a concentration up to 500 nM (see 
the gelatinolytic activity of the PAO1-Sec in Fig. 3E and 5D, right-hand panels, and [32]). 
Exposure of recombinant human pro-uPA to this secretome actually results in its activation, 
as judged by both immunoblot analysis (Fig. 1C) and proteolytic activity measurement (Fig. 
1D). This processing is already detectable with a 1/2,500 dilution (i.e., 0.04 %, v/v) of the 
PAO1-Sec, while a 1/100 dilution (i.e., 1 %, v/v) results, as observed with purified LasB, in a 
further processing of the A-chain (Fig. 1C). In order to evaluate the role of LasB as a major 
pro-uPA activating enzyme within the pseudomonal secretome, we analyzed the capacity of 
the secretome from an isogenic LasB-deficient strain (i.e., PDO240) to activate the human 
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zymogen. Using the PDO240-Sec, a significant pro-uPA activation is observed (Fig. 1E and 
1F), although limited as compared to that produced with the PAO1-Sec.  
Altogether these results suggest that LasB is indeed a major pseudomonal pro-uPA activator, 
although P. aeruginosa also secretes one or several other pro-uPA activator(s). 
 
Identification of PIV as a potent pro-uPA activator 
In order to identify the unknown pro-uPA activator(s) expressed within the pseudomonal 
secretome, pro-uPA was exposed to the PDO240-Sec in the presence of selective protease 
inhibitors, before analyzing pro-uPA activation by immunoblot. Pro-uPA activation by the 
LasB-deficient PDO240-Sec is not affected by metallo-, cysteine- or aspartic-protease 
inhibitors (i.e., OPA, E-64 and pepstatin A, respectively), while it is clearly reduced, although 
not abrogated, in the presence of the wide spectrum Ser-protease inhibitor benzamidine (Fig. 
2A). Consistently, and while the cation chelator OPA totally inhibits pro-uPA activation by 
100 nM purified LasB (Fig. 2B, right-hand panel), it is not sufficient to fully repress 
activation of the zymogen by the PAO1-Sec, although activation is drastically impaired (Fig. 
2B, left-hand panel). This reflects both a major LasB-dependent and a minor LasB- and 
metalloprotease-independent pro-uPA activation by the PAO1-Sec. As observed with the 
PDO240-Sec, the metalloprotease-independent pathway of activation is actually sensitive to a 
Ser-protease inhibitor, as indicated by the almost total abrogation of activation provided by 
the combination of OPA and benzamidine, whereas none of the other inhibitor combinations 
(OPA/E-64, OPA/pepstatin A) adds any further inhibition over that provided by OPA alone 
(Fig. 2B, left-hand panel). Taken together, these observations confirm that, besides LasB, 
activation of human pro-uPA by the pseudomonal secretome also involves a Ser-protease 
activity.  
Among the pseudomonal secreted Ser-proteases is PIV, also referred to as PrpL or Ps-1 [34-
36]. This enzyme, which activity was reported to be affected, but not completely blocked, by 
benzamidine [36], targets substrates bearing a Lys residue at the P1 position of the sessile 
peptide bond [23, 36]. Such inhibitor and substrate specificities thus share similarities with the 
metalloprotease-independent pro-uPA activation that is observed upon its exposure to 
pseudomonal secretomes. In support to the assumption that PIV may be a pro-uPA activator, 
it must be noted that PIV is expressed to significant and similar levels in both the PAO1 and 
PDO240 secretomes, as demonstrated by evaluation of the global gelatinolytic activity of the 
secretomes using zymography (Fig. 3E). Indeed, the gelatinolytic profile of the PAO1-Sec 
identifies, under the particular electrophoretic conditions used, three major components with 
Mr values of ≈ 52,000, ≈ 167,000 and ≥250,000, which, based on previous reports [15, 35], 
correspond to the alkaline protease/AprA, LasB, and PIV, respectively. The gelatinolytic 
profile of the PDO240-Sec shows the alkaline protease/AprA and PIV components, with 
activities similar to those observed in the PAO1-Sec, while lacking, as expected, the LasB 
component. In order to ascertain that PIV can be a pro-uPA activator, the DNA encoding for 
mature PIV was cloned from the PAO1 genome [37] and then inserted into a prokaryotic 
expression plasmid encoding for a translation product bearing an aminoterminal (His)6-tag, as 
schematically depicted in Fig. 3A, following a procedure previously described for a number 
of eukaryotic Ser-proteases [38, 39]. As expected, plasmid transformation in E. coli, followed 
by protein expression, extraction under denaturating conditions and purification, yields a 
major Mr  30,000 fusion protein (Fig. 3B). It is of note that the two-step purification 
procedure (i.e., pH-dependent affinity chromatography on Ni-NTA followed by a second Ni-
NTA chromatography using an imidazol concentration gradient) results in a rather pure 
preparation of recombinant PIV, which however remains slightly contaminated by a Mr  
27,000 protein (Fig. 3B). This latter contaminant is also present in the final preparation of an 
E. coli-expressed, (His)6-tagged protein generated through an identical procedure and taken as 
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a negative control, in this case the Mr  14,500 D1 domain of the uPA receptor, uPAR 
(uPAR-D1, Fig. 3B). SDS-PAGE performed under reducing conditions indicates that, upon 
dialysis-based protein refolding, recombinant PIV readily proceeds itself into smaller species 
with Mr  20,000 and ≈ 17,000 (Fig. 3B), a feature which is also observed when proteins are 
analyzed under nonreducing conditions (data not illustrated). These truncated PIV species 
remain reactive with an Ab directed against the His-tag (Fig. 3C), demonstrating that they 
result from cleavage of the enzyme within its carboxyterminal region. Remarkably, such PIV 
autoprocessing has already been reported for naturally produced, as well as for recombinantly 
expressed PIV, and was found not to affect the enzyme proteolytic activity [23, 35, 37, 40, 
41]. Accordingly, our recombinant PIV preparation is active towards a known PIV 
chromogenic susbstrate, chromozyme PL [34] (Fig. 3D) and appears, upon gelatin 
zymography, as a high Mr doublet species (Fig. 3E). In contrast, the preparation of 
recombinant uPAR-D1 is devoid of any peptidase/proteinase activity in both assays (Fig. 3D 
and 3E). 
Exposure of recombinant human pro-uPA to increasing concentrations of recombinant PIV 
(7.5-200 nM) results in a progressive conversion of single-chain pro-uPA into two-chain, 
active uPA, with uPA activity reaching up to 80 % of the activity of an equivalent amount of 
purified uPA, whereas, in contrast, recombinant uPAR-D1 leaves pro-uPA unchanged and 
inactive (Fig. 4A and 4B). These data were validated by the observation that native PIV (100 
nM), directly purified from the extracellular medium of pseudomonal cultures, also targets 
and activates the zymogen (Fig. 4A and 4B). It is of note that, for a high PIV concentration 
(i.e., over 100 nM PIV), a further processing of the uPA A-chain is observed, leading to the 
generation of a Mr  13,000 species which results from hydrolysis of the Lys
23
-Tyr
24
 peptide 
bond (Fig. 4A and Table 1). In addition, exposure of pro-uPA to recombinant PIV in the 
presence of selective protease inhibitors revealed that, as observed with bacterial secretomes, 
PIV-induced pro-uPA activation is drastically sensitive to benzamidine, whereas it is not 
affected by the other tested inhibitors (data not illustrated). Finally, kinetic parameters of pro-
uPA activation by native PIV were found to be kcat = 0.73 ± 0.04 s
-1
, Km = 6.2 ± 0.65 M and 
kcat/Km 0.12 ± 0.01 M
-1
 s
-1
. 
Altogether, our results thus demonstrate that within the pseudomonal secretome, not only 
LasB, but also PIV targets and activates pro-uPA. 
 
Identification of other substrates for pseudomonal proteases within the host Plg 
activation system 
We further analyzed whether PIV cleaves other known LasB targets within the human Plg 
activation system (i.e., uPAR, PAI-1 and pro-MMP-2), and, more generally, whether 
pseudomonal proteases can directly process Plg [32, 42-44].  
Exposure of Plg to either purified LasB (10 nM) or to 1 % of the LasB-expressing PAO1-Sec 
results in the generation of identical new molecular species, including a doublet with Mr  
72,000/65,000, and a singlet with Mr  40,000 (Fig. 5A). These species are distinct from the 
88/84 kDa A-chain, and from the 28 kDa B-chain produced upon Plg activation by uPA (data 
not illustrated). In line with this, LasB-processed Plg does not show any proteolytic activity 
towards a synthetic Pm chromogenic substrate (data not illustrated). Aminoterminal 
microsequencing allowed to establish that these Plg-derived species result from hydrolysis of 
the Ser
441
-Val
442 
and Val
442
-Val
443 
peptide bonds within human Plg (Table 1). They thus 
correspond to two glycosylation variants of angiostatin, encompassing the Plg kringle 
domains 1 to 4 (Mr  72,000/65,000), and to mini-Plg, composed of the inactive catalytic 
domain and of the kringle domain 5 (Mr  40,000). For higher LasB concentrations (i.e., 100 
nM) or with 20 % PAO1-Sec, these Plg fragments are further processed into Mr  
43,000/39,000 and 29,000 forms, which were found to result from further carboxyterminal 
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processing of both angiostatin and mini-Plg. By contrast, neither the LasB-deficient PDO240-
Sec, nor recombinant PIV has any detectable effect on the structure and activity of human Plg 
(Fig. 5A and data not shown, respectively). 
As we recently reported [32], it was confirmed that purified LasB (100 nM), as well as the 
PAO1-derived secretome (20 %), convert recombinant soluble uPAR (Mr  55,000) into a Mr 
 45,000 D2D3 truncated species lacking the shed aminoterminal D1 domain (Fig. 5B), 
which reflects hydrolysis within the uPAR D1-D2 linker region. Exposure of uPAR either to 
the PDO240-Sec or to recombinant PIV shows no evidence for a proteolytic processing of this 
important cell receptor (Fig. 5B). 
Furthermore, LasB was reported to target and inactivate PAI-1 [42]. Accordingly, LasB at 
100 nM, as well as the PAO1-Sec (20 %), process recombinant PAI-1 (Mr  57,000) into a 
slightly shorter molecular species with Mr  54,000 (Fig. 5Cl). This feature has also been 
reported for other bacterial thermolysin-related proteases [45], in which case it corresponds to 
cleavage within the carboxyterminal domain of the serpin, in the vicinity of the reactive center 
loop. By contrast, PAI-1 was not processed at all using the LasB-deficient secretome or 
recombinant PIV (Fig. 5C). 
Finally, this study confirms that LasB at 100 nM, as well as the PAO1-Sec in the range 1-20 
%, transform pro-MMP-2, as it is spontaneously released by human vascular fibroblasts in 
their culture medium with a Mr  63,000 [28], into the Mr  57,000 active form of the 
enzyme, as judged by gelatin zymography (Fig. 5D) [43, 44]. Activation of fibroblast-derived 
pro-MMP-2 by purified LasB was also confirmed by protease activity measurement towards a 
MMP-selective fluorigenic substrate (data not shown). By contrast, under conditions which 
trigger efficient pro-uPA activation, recombinant PIV or PIV naturally expressed by the 
PDO240 strain, leave pro-MMP-2 unaffected (Fig. 5D). 
Similar results regarding the absence of Plg, uPAR, PAI-1 or pro-MMP-2 processing by PIV, 
were also obtained using the purified native protease (data not shown). 
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DISCUSSION 
A number of pathogenic bacteria take profit on the host Plg system to promote their own 
spread and invasion through host tissues and physiological barriers, in a way that mimics that 
observed for malignant tumor cells [7-9]. In the case of P. aeruginosa, Plg/Pm binding at the 
bacterial surface has been reported for a number of reference and clinical isolates [22, 46, 47]. 
Moreover, bound Pm promotes invasion of P. aeruginosa within fibrin and reconstituted 
basement membrane matrices [22]. However, in contrast to S. aureus and Y. pestis [7, 9, 13], 
P. aeruginosa had not been reported so far to display any activator for either pro-uPA, tPA or 
Plg. 
In the present study, we establish that P. aeruginosa secretes proteases that directly 
activate the zymogen form of human uPA, including the thermolysin-like metallopeptidase 
LasB and the Ser-protease PIV. With a kcat/Km of 0.55 M
-1
 s
-1
, LasB appears as a potent pro-
uPA activator, with a specificity constant in the range of that observed for Pm (kcat/Km of Pm 
= 1.3 M-1 s-1), whereas PIV is about five times less efficient than LasB (kcat/Km = 0.12 M
-1
 
s
-1
). Still both proteases activate pro-uPA much more efficiently than the S. aureus-expressed, 
thermolysin-like protease aureolysin (kcat/Km of aureolysin 0.003 M
-1
 s
-1
)[13]. Remarkably, 
besides P. aeruginosa, several pathogenic bacteria that express thermolysin-like peptidases, 
including S. aureus[13], Burkholderia cepacia and Serratia marcescens (Beaufort et al., 
unpublished results), also display pro-uPA activating capacities. It is thus tempting to propose 
that pro-uPA activation might be a feature common to bacterial M4-related peptidases and, 
thus, a property shared by other pathogenic bacterial species. 
 Within human tissues, (pro-)uPA is locally expressed at low levels by epithelial, 
endothelial and stromal cells [11, 12]. Upon inflammation or infection, its expression by these 
cells is increased, while it is also massively released from neutrophils recruited at the site of 
inflammation/infection, where plasma proteins, including Plg, also exudate [11, 12]. As pro-
uPA is positioned upstream in the auto-amplified uPA/Pm/MMPs proteolytic loop, its 
activation by bacterial enzymes certainly results in an efficient triggering and maintenance of 
this host proteolytic system. Concerning Plg, the zymogen was not processed into active Pm 
by any of the pseudomonal proteases. Plg was, however, cleaved by LasB, but not by PIV, 
into (i) mini-Plg, that can be further converted into mini-Pm [13], and (ii) angiostatin, that 
displays the interesting capacity to dampen leukocytes migration, and might thus provide 
bacteria with immunoevasive capacities [48]. Inactivation of host serpins and/or activation of 
pro-MMPs, are other known features of bacterial proteases that may allow a pathogen to use 
one of the major extracellular proteolytic system of the host for its own dissemination [7, 13, 
43, 44]. With this respect, we confirmed that LasB neutralizes PAI-1 [42], whereas it activates 
pro-MMP-2 [43, 44], thus further participating to the bacterial-driven deregulation of the 
otherwise tightly regulated Plg activation system. By contrast, PIV leaves both substrates 
unaffected. Of note is the fact that the proteolytic processing of the other principal Plg 
activator, tPA, by pseudomonal proteases was not investigated here, since its activation is 
promoted by its binding to fibrin rather than by proteolysis [11].  
 Although the effects of bacteria and bacterial compounds on the host Plg activation 
system have been extensively analyzed [7], the reciprocal activity of the Plg system on 
bacteria has been poorly investigated so far, with exception of (pro-)uPA, which promotes 
pseudomonal growth and enhances the bacterial proteolytic activity [49, 50]. Interestingly, we 
found that both LasB and PIV process the A-chain of (pro-)uPA, a feature which prevents 
uPA binding to its cellular receptor uPAR [51]. Along with this, LasB targets the D1-D2 
linker region within uPAR, which abrogates uPA/uPAR interaction [32]. Altogether, we 
speculate that the Pseudomonas-dependent disruption of the (pro-)uPA/uPAR complex might 
increase the bioavailability of the otherwise membrane-anchored (pro-)uPA, thereby 
promoting bacterial growth. 
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In contrast to the rather well-characterized LasB, only little information is currently 
available concerning PIV. PIV is widely expressed among reference and clinical isolates [37, 
52], and is a potent virulence factor in eye and lung infection models [35, 37, 41]. 
Interestingly, this Ser-peptidase appears to be clearly distinct from eukaryotic Ser-proteases. 
On one hand, PIV readily processes its own mature catalytic domain (≈ 30 kDa) into smaller 
20 and 17 kDa fragments, a cleavage that does not impair its proteolytic activity [40, 41]. On 
the other hand, it displays a bulky, 186 amino acids pro-domain, which has been proposed to 
prevent intracellular auto-processing, or to act as a chaperone protein [41]. We now establish 
that replacement of the PIV pro-domain by a short, 17 residues sequence, actually leads to an 
active form of the enzyme, although it is still N-terminally extended. This suggests that PIV 
activation does not result from an insertion of the N-terminus of the mature catalytic domain 
into a cleft near the active site, triggering a conformational rearrangement of the latter as 
observed with eukaryotic Ser-proteases [53], but rather from uncovering of the already 
preexisting active site, as described e.g. for subtilisin-like peptidases [54]. Concerning the 
PIV substrate specificity, this protease targets peptide bonds bearing a basic residue in the P1 
position [23], whereas LasB targets peptide bonds bearing a bulky or apolar residue in the P1' 
position [4]. As a consequence, and although these two proteases belong to different protease 
families, they both hydrolyse the unique activation cleavage site within human pro-uPA, i.e., 
Lys
158
-Ile
159
. In contrast, a number of LasB substrates (e.g., Plg, uPAR, PAI-1, pro-MMP-2; 
Table 1) are not affected at all by PIV, or are processed at different peptide bonds (e.g., the 
uPA A-chain; Table 1).  
 In conclusion, the ubiquitous bacterium P. aeruginosa expresses proteases, including 
the well-known thermolysin-like metallopeptidase LasB, and the more recently described 
PIV, which both combine to hijack the host Plg system, primarily via pro-uPA activation, and, 
in the case of LasB, via PAI-1 inactivation and pro-MMP-2 activation. Such processes might 
constitute an important virulence mechanism, which may well utilize other pathogenic 
bacteria expressing similar extracellular proteases.  
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TABLES 
Table 1. Cleavage sites for LasB and PIV within components of the human Plg 
activation system  
 
 
 
 
Substrate 
 
 
 
Peptide bonds cleaved 
by LasB 
 
 
 
Peptide bonds cleaved 
by PIV 
 
 
pro-uPA 
 
 
 
 PRFK
158 
-
 159IIGG(a) 
 SNKY
24  
-
  25FSNI(a) 
 
 
 
 PRFK158 - 159IIGG(a) 
 VSNK23  -  24YFSN(a) 
 
 
 
Plg 
 
 
 
 TEAS
441 
-
 442VVAP(a) 
 EASV
442 
-
 443VAPP(a) 
 
 
 
 
 
       none 
 
 
 
uPAR 
 
 
 
 SGRA
84  
-
  85VTYS(b) 
 RAVT
86  
-
  87YSRS(b) 
 LDVQ
279 
-
 280YRSG(b) 
 
 
 
 
       none 
 
 
pro-MMP-2 
 
 
 DVAN
80  
- 
81YNFF(c) 
 
 
 
       none 
 
 (a)
: peptide bonds hydrolyzed by LasB and/or PIV were identified by aminoterminal 
microsequencing, as described in the Experimental section; 
(b)
: according to [32];  
(c)
: according to the known activation cleavage site within human pro-MMP-2 
(www.uniprot.org);  
none: no cleavage observed. 
Preferred amino acids in the P1 (for PIV) and P1´ (for LasB) position of the cleavage site are 
set in bold. 
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FIGURE LEGENDS 
Figure 1: Activation of human pro-urokinase by purified LasB, or by the secretomes of 
P. aeruginosa LasB-expressing or LasB-deficient strains of P. aeruginosa. 
Purified human pro-uPA (200 ng,  450 nM) was left untreated (NT), exposed to its canonical 
activator plasmin (Pm, 45 nM), to increasing concentrations of purified LasB (A,B), or to 
increasing quantities (expressed as a percentage of the final volume of the reaction mixture) 
of the secretome either from the LasB-expressing pseudomonal strain PAO1 (PAO1-Sec; C, 
D) or from the isogenic, LasB-deficient strain PDO240 (PDO240-Sec; E,F), for 60 min at 
37°C. (A,C,E) Proteins were analyzed by immunoblotting using a chicken anti-uPA pAb 
(dilution 1/2,000), as described in the Material and Methods section. Portions of the films 
corresponding to the location of the relevant molecular species, located by an arrow on the 
left-hand side, are shown and their apparent molecular mass (Mr) is indicated on the right-
hand side. One out of three analyses showing similar results is illustrated. (B, D, F) In 
parallel, uPA activity was assayed towards a selective chromogenic substrate (Pefachrome 
uPA). The proteolytic activity of 200 ng of purified uPA was used as an external positive 
control and corresponds to 100% activation of the zymogen present in the assay. Histograms 
represent mean + SEM of 3 independent experiments. Note that pro-uPA, LasB and the 
PAO1-Sec and PDO240-Sec per se have no or minimal activity on Pefachrome uPA.  
 
Figure 2: Activation of human pro-urokinase by a benzamidine-sensitive secreted 
pseudomonal protease. 
Pro-uPA was either left untreated (NT), or exposed to 1% (v/v) of PDO240-Sec (A), to 1% 
(v/v) PAO1-Sec (B, left-hand panel), or to 100 nM LasB (B, right-hand panel), for 60 min at 
37°C, in the presence or absence of the following protease inhibitors: orthophenanthroline 
(OPA, 10 mM), benzamidine (Benz., 5 mM), E64 (10 μM) or pepstatin A (Pep., 5 μM), which 
were either added alone, or in combination (Mix, combination of all four inhibitors). Pro-uPA 
activation was then evaluated by immunoblotting (n=3), as described in the legend to Fig. 1.  
 
Figure 3: Production of recombinant active pseudomonal PIV. 
(A) Schematic structure comparison of the natural and E. coli-expressed PIV proteins (upper 
and lower panels, respectively). (B,C) Preparations of E. coli-expressed PIV, or uPAR-D1 
(used as a control, nonprotease recombinant protein preparation), either purified or purified 
and refolded, were analyzed by SDS-PAGE under reducing conditions followed by transfer 
onto a PVDF membrane and Coomassie blue staining (B), or immunoblotting using an anti-
His mAb (PentaHis, 1 μg/ml, C). (D,E) Refolded recombinant PIV and uPAR-D1 
preparations were evaluated for peptidase (D) and proteinase (E) activity, using the 
chromogenic substrate Chromozym PL, or gelatin zymography, respectively, as detailed in 
the Experimental section. For zymography, a reference gelatinolyc profile was provided by 
the bacterial secretomes originating from the pseudomonal PAO1 and PDO240 strains. 
Results obtained for PIV and uPAR-D1 batches representative of 2 to 3 independent 
preparations are illustrated.  
 
Figure 4: Activation of human pro-urokinase by recombinant pseudomonal PIV. 
Pro-uPA was either left untreated (NT), or exposed to Pm, to increasing concentrations of 
recombinant PIV (rPIV, 7.5-200 nM), to recombinant uPAR-D1 (200 nM), or to native PIV 
(nPIV, 100 nM), for 60 min at 37°C. Immunoblot analysis for pro-uPA processing (A, 
representative of 2 experiments) and measurement of uPA activity (B, mean + SEM, n=4) 
were then performed exactly as described in the legend to Fig.1. Note that pro-uPA, rPIV, 
uPAR-D1 or nPIV per se, have no appreciable direct activity on the uPA substrate. 
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Figure 5: Processing of components of the human Plg activation system by pseudomonal 
proteases. 
Human Plg ( 200 nM), recombinant human uPAR ( 20 nM), recombinant human PAI-1 ( 
20 nM), or fibroblast-derived culture medium containing pro-MMP-2 were either left 
untreated (NT), or exposed to pseudomonal proteases, either pure, or as they are expressed 
within the PAO1-Sec or the PDO240-Sec, as indicated in the legends to Fig. 1 and 4. (A) The 
proteolytic processing of Plg was analyzed by SDS-PAGE (1 μg Plg per lane) followed by 
Coomassie blue staining. (B,C) uPAR and PAI-1 processing were evaluated by immunoblot 
(10 ng protein per lane) using an anti-uPAR mAb directed against the D2 domain (#3932, 
0.05 μg/ml) (B) or an anti-PAI-1 mAb recognizing the seuquence 24-158 of human PAI-1 (C-
9, 0.4 μg/ml) (C). (D) (Pro-)MMP-2 activity was detected by gelatin zymography (20 μl of 
reaction mixture per lane), with the gelatinolytic profiles of the bacterial secretomes depicted 
in the right-hand panel. Note that the alkaline protease/AprA activity is higher in the 
PDO240-Sec as compared to the PAO1-Sec. Results illustrated are representative of 2 to 3 
independent experiments.  
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